9MH MedX Health Corp.

MedX Health Corp. Announces Launch of Skin Scanning Service in the Netherlands

MedX Health Corp. (“MedX”) (TSX-V: MDX) is pleased to announce that its channel partner, Nationale Healthcheck (“NH”), has launched its skin assessment service using SIAscopy in the Netherlands.

NH has commenced the installation of its proprietary diagnosis and triage system addressing selected illnesses including cardiac disease, diabetes, skin cancer and Post Traumatic Stress Disorder (“PTSD”). NH has selected MedX’s SIAscopy technology for its skin assessment module with remote diagnosis. The service is reimbursed through the Dutch health insurance system. NH has expressions of interest from more than 250 health service companies with more than 70 firm orders, and is planning to supply this service across the entire country. MedX has begun making deliveries as NH rolls out their program over the coming months.

“There were almost 16,000 skin cancer cases in Holland last year, a 7.5% increase over the previous year, as reported by the NL Times, so checking moles and lesions is an essential part of our product offering,” stated Paul Vlaanderen, CEO of Nationale Healthcheck. “We selected MedX’s technology as it offers a unique differentiator in skin assessment within our product offering. It delivers outstanding mole imagery generated from up to 2 mm below the skin to deliver 5 images – a significant advantage in assessing the risk associated with a mole or lesion.”

“Paul and his team are excellent business partners who have developed an outstanding system for assessing risk in a number of health fields. We are delighted to be able to be part of such an innovative approach to healthcare.” said Rob von der Porten, MedX CEO.

About MedX

MedX, headquartered in Mississauga, Ontario, is a leading medical device company focused on skin cancer with its SIAscopy technology. This technology is imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. The devices are sold to physicians and clinics, as well as being deployed in pharmacies and remote clinics from where the images are sent to dermatologists who perform a diagnosis. These products are Health Canada, FDA (US), ARTG and CE approved for use in Canada, the US, Australia, the European Union and Turkey. SIAMETRICS™ is a unique product used in a specialized market for research into the clinical effectiveness of medical treatments of certain skin conditions. MedX also designs, manufactures and distributes quality laser and light therapy technologies for use in numerous medical settings, approved in major jurisdictions, to provide drug free and non-invasive treatment of tissue damage and pain. For more information and a complete profile of MedX and its products visit www.medxhealth.com

About Nationale Healthcheck BV

Nationale Healthcheck is a Netherlands-based company founded by a group of successful entrepreneurs, with the mission to improve the deliverability of preventative healthcare in the Netherlands. The company has developed a specially designed National Healthcheck mobile case containing multiple medical tests, including heart and blood vessels, lungs, stress, blood pressure, saturation, biometrics, cholesterol, glucose and skin assessment using MedX’s SIAscopy. Testing can be completed during visits to companies’ offices, senior’s centres and sports clubs, or at locations visited by a specially outfitted Healthcheck bus. All tests are assessed by a doctor, including a dermatologist for the assessment of SIAscopy scans, with a full report prepared and sent to the patient. Healthcheck has collaborated with Dutch Health Insurers which provide full reimbursement of all the tests conducted by Nationale Healthcheck.

For more information and a complete profile of Nationale Healthcheck visit www.nationalehealthcheck.nl/home/

EN
29/11/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MedX Health Corp.

 PRESS RELEASE

MedX to Present at Benzinga Healthcare Conference on September 30th

Mississauga, Ontario--(Newsfile Corp. - September 29, 2021) - (TSXV: MDX) ("MedX" or the "Company"), a global leader in teledermatology, is pleased to announce its participation in the Benzinga Healthcare Small Cap Conference (the "Conference"), taking place virtually on Thursday, September 30th at 4:40 PM ET. MedX President & CEO, Sylvain Desjeans, along with Mike Druhan, President Dermatological Services, will present the Company's vision for scaling access to its unique dermatological image capture technology and fully integrated telemedicine platform, DermSecure®. The screening platform ...

 PRESS RELEASE

MedX Health Corp.’s SIAscopy Technology Being Introduced to the Span...

MISSISSAUGA, Ontario--(BUSINESS WIRE)-- MedX Health Corp. (“MedX”) (TSX-V: MDX) announced that it has shipped an initial order in excess of $120,000 of its SIAscopy technology to Spain through its marketing partnership with OncoTech LLC. “Completing this large order early in the second quarter reinforces the growing interest in our technology as a pain-free non-invasive skin assessment tool,” noted Rob von der Porten, MedX's CEO. “OncoTech sees this as a first step in gaining awareness followed by further market penetration i...

 PRESS RELEASE

MedX Health Corp. Announces 2017 Year End Results and Granting of Shar...

MISSISSAUGA, Ontario--(BUSINESS WIRE)-- MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced its results for the year ended December 31, 2017, which are also available on SEDAR (www.sedar.com). The Company reported revenue of $1,093,239 for the year ended December 31, 2017, an increase of 34% from revenue of $817,055 for the year ended December 31, 2016. Sales from the Company's therapeutic laser line grew by $341,488 during 2017, while revenue from SIAscopy, the Company’s skin assessment technology, was $65,304...

 PRESS RELEASE

MedX Health Corp. Adds Experienced Medical Device Professional, Scott ...

MISSISSAUGA, Ontario--(BUSINESS WIRE)-- MedX Health Corp. (“MedX”) (TSX-V: MDX) announced today that Scott Spearn, an experienced medical device executive, joined the MedX team as President. Mr. Spearn has successfully built sales and distribution channels for medical devices across Canada, the United States and Latin America. His focus will be on developing and expanding MedX’s North American and international sales. Mr. Spearn will report to Robert von der Porten, CEO. “With the completion of successful financings and the f...

 PRESS RELEASE

MedX Health Corp. Announces Investor Relations Agreement

MISSISSAUGA, Ontario--(BUSINESS WIRE)-- MedX Health Corp. (“MedX” or the “Company”) (TSX-V:MDX). The Company announces that it has received notice from the TSX-V accepting an Investor Relations Agreement entered into with Mi3 Communications Financières Inc. (the “Consultant”) with an effective date of December 1, 2017. Under the terms of the Agreement, the Consultant will carry out activities to develop the Eastern Canada shareholder base of the Company, and the Company will pay to the Consultant a monthly consideration of $5,000, tog...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch